Assess whether to resubmit, meet, or pause the program (46fb8c)

SITUATION After a DSMB note on an imbalance that is not yet a signal, 505(b)(2) literature-to-product bridge table is what pharmacovigilance medical reviewer can touch in a mid-size sponsor after a complete response letter. Pharma & Life Sciences will live with To resubmit, meet, versus Pause the program on this CMC and Development Pathways file.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend To resubmit, meet, from 505(b)(2) literature-to-product bridge table; Pause the program is what the extract actually supports after a DSMB note on an imbalance that is not yet a signal. 3. A DSMB note on an imbalance that is not yet a signal never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to resubmit, meet, or. 4. Two facts in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / CMC and Development Pathways packet (505(b)(2) literature-to-product bridge table after a DSMB note on an imbalance that is not yet a signal). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a DSMB note on an imbalance that is not yet a signal, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform